242 related articles for article (PubMed ID: 19061859)
1. Surface plasmon resonance characterization of specific binding of polyglutamine aggregation inhibitors to the expanded polyglutamine stretch.
Okamoto Y; Nagai Y; Fujikake N; Akiko Popiel H; Yoshioka T; Toda T; Inui T
Biochem Biophys Res Commun; 2009 Jan; 378(3):634-9. PubMed ID: 19061859
[TBL] [Abstract][Full Text] [Related]
2. Delivery of the aggregate inhibitor peptide QBP1 into the mouse brain using PTDs and its therapeutic effect on polyglutamine disease mice.
Popiel HA; Nagai Y; Fujikake N; Toda T
Neurosci Lett; 2009 Jan; 449(2):87-92. PubMed ID: 18603372
[TBL] [Abstract][Full Text] [Related]
3. Disruption of the toxic conformation of the expanded polyglutamine stretch leads to suppression of aggregate formation and cytotoxicity.
Popiel HA; Nagai Y; Onodera O; Inui T; Fujikake N; Urade Y; Strittmatter WJ; Burke JR; Ichikawa A; Toda T
Biochem Biophys Res Commun; 2004 May; 317(4):1200-6. PubMed ID: 15094397
[TBL] [Abstract][Full Text] [Related]
4. A toxic monomeric conformer of the polyglutamine protein.
Nagai Y; Inui T; Popiel HA; Fujikake N; Hasegawa K; Urade Y; Goto Y; Naiki H; Toda T
Nat Struct Mol Biol; 2007 Apr; 14(4):332-40. PubMed ID: 17369839
[TBL] [Abstract][Full Text] [Related]
5. Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila.
Nagai Y; Fujikake N; Ohno K; Higashiyama H; Popiel HA; Rahadian J; Yamaguchi M; Strittmatter WJ; Burke JR; Toda T
Hum Mol Genet; 2003 Jun; 12(11):1253-9. PubMed ID: 12761040
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationship study on polyglutamine binding peptide QBP1.
Tomita K; Popiel HA; Nagai Y; Toda T; Yoshimitsu Y; Ohno H; Oishi S; Fujii N
Bioorg Med Chem; 2009 Feb; 17(3):1259-63. PubMed ID: 19121945
[TBL] [Abstract][Full Text] [Related]
7. HSPB7 is the most potent polyQ aggregation suppressor within the HSPB family of molecular chaperones.
Vos MJ; Zijlstra MP; Kanon B; van Waarde-Verhagen MA; Brunt ER; Oosterveld-Hut HM; Carra S; Sibon OC; Kampinga HH
Hum Mol Genet; 2010 Dec; 19(23):4677-93. PubMed ID: 20843828
[TBL] [Abstract][Full Text] [Related]
8. Amino acid sequence requirements of peptides that inhibit polyglutamine-protein aggregation and cell death.
Ren H; Nagai Y; Tucker T; Strittmatter WJ; Burke JR
Biochem Biophys Res Commun; 2001 Nov; 288(3):703-10. PubMed ID: 11676500
[TBL] [Abstract][Full Text] [Related]
9. Protein transduction domain-mediated delivery of QBP1 suppresses polyglutamine-induced neurodegeneration in vivo.
Popiel HA; Nagai Y; Fujikake N; Toda T
Mol Ther; 2007 Feb; 15(2):303-9. PubMed ID: 17235308
[TBL] [Abstract][Full Text] [Related]
10. Multi-domain misfolding: understanding the aggregation pathway of polyglutamine proteins.
Saunders HM; Bottomley SP
Protein Eng Des Sel; 2009 Aug; 22(8):447-51. PubMed ID: 19589877
[TBL] [Abstract][Full Text] [Related]
11. Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity.
Sakahira H; Breuer P; Hayer-Hartl MK; Hartl FU
Proc Natl Acad Sci U S A; 2002 Dec; 99 Suppl 4(Suppl 4):16412-8. PubMed ID: 12189209
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases.
Popiel HA; Takeuchi T; Burke JR; Strittmatter WJ; Toda T; Wada K; Nagai Y
Neurotherapeutics; 2013 Jul; 10(3):440-6. PubMed ID: 23504628
[TBL] [Abstract][Full Text] [Related]
13. Analyzing the aggregation of polyglutamine-expansion proteins and its modulation by molecular chaperones.
Kubota H; Kitamura A; Nagata K
Methods; 2011 Mar; 53(3):267-74. PubMed ID: 21195182
[TBL] [Abstract][Full Text] [Related]
14. [Selective degradation of expanded polyglutamine proteins by their specific recognition with QBP1].
Nagai Y; Nukina N
Rinsho Shinkeigaku; 2011 Nov; 51(11):1108-10. PubMed ID: 22277499
[TBL] [Abstract][Full Text] [Related]
15. Mimicking proteasomal release of polyglutamine peptides initiates aggregation and toxicity.
Raspe M; Gillis J; Krol H; Krom S; Bosch K; van Veen H; Reits E
J Cell Sci; 2009 Sep; 122(Pt 18):3262-71. PubMed ID: 19690053
[TBL] [Abstract][Full Text] [Related]
16. [Molecular therapy targeting protein misfolding and aggregation for the polyglutamine diseases].
Nagai Y
Rinsho Shinkeigaku; 2009 Nov; 49(11):913-6. PubMed ID: 20030247
[TBL] [Abstract][Full Text] [Related]
17. Peptide-based therapeutic approaches for treatment of the polyglutamine diseases.
Takeuchi T; Popiel HA; Futaki S; Wada K; Nagai Y
Curr Med Chem; 2014; 21(23):2575-82. PubMed ID: 24533807
[TBL] [Abstract][Full Text] [Related]
18. The structure of a polyQ-anti-polyQ complex reveals binding according to a linear lattice model.
Li P; Huey-Tubman KE; Gao T; Li X; West AP; Bennett MJ; Bjorkman PJ
Nat Struct Mol Biol; 2007 May; 14(5):381-7. PubMed ID: 17450152
[TBL] [Abstract][Full Text] [Related]
19. Endoplasmic reticulum chaperone GRP78 suppresses the aggregation of proteins containing expanded polyglutamine tract.
Yamagishi N; Magara S; Tamura S; Saito Y; Hatayama T
Biochem Biophys Res Commun; 2012 Jun; 422(3):527-33. PubMed ID: 22627132
[TBL] [Abstract][Full Text] [Related]
20. Folding of polyglutamine chains.
Chopra M; Reddy AS; Abbott NL; de Pablo JJ
J Chem Phys; 2008 Oct; 129(13):135102. PubMed ID: 19045125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
